European Society of Gastrointestinal Endoscopy position statement


  • Dawn O'Shea
  • Univadis Medical News
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The European Society of Gastrointestinal Endoscopy (ESGE) has published a position statement on the role of gastrointestinal endoscopy in screening for digestive tract cancers.

Key recommendations include the following:

For average-risk populations, ESGE recommends population-based faecal immunochemical testing (FIT) screening programmes for individuals 50-75 years with average risk for colorectal cancer (CRD)

In high-risk populations, endoscopic screening for gastric cancer should be considered for individuals aged >40 years. Its use for intermediate risk should be based on local settings.

For oesophageal and pancreatic cancer, endoscopic screening should be considered only in high-risk individuals:

For squamous cell carcinoma, in those with a personal history of head and neck cancer, achalasia, or previous caustic injury.

For Barrett’s oesophagus (BE)-associated adenocarcinoma, in those with long-standing (>5 years) gastro-oesophageal reflux disease symptoms (GORD) and multiple risk factors (age ≥50 years, white race, male sex, obesity, first-degree relative with BE or oesophageal adenocarcinoma [EAC].

For pancreatic cancer screening, endoscopic ultrasound may be used in selected high-risk patients such as those with a strong family history and/or genetic susceptibility.